Pharmaceuticals News & Press Release Distribution

Pharmaceuticals

APAC
Global

Hummingbird Bioscience Announces First Patient Dosed in Phase 1 Clinical Trial of HMBD-001 in Advanced HER3-Expressing Solid Malignancies

HOUSTON and SINGAPORE, Dec. 6, 2021 /PRNewswire/ -- Hummingbird Bioscience, an innovative clinical-stage biotech company focused on developing precision therapies against hard-to-drug targets in cancer and autoimmune disease, and Cancer Research UK, the world's leading cancer charity, today annou...

2021-12-06 17:30 2061

Odyssey Announces Agreement to Combine with BenevolentAI

LONDON and AMSTERDAM, Dec. 6, 2021 /PRNewswire/ -- Odyssey Acquisition S.A. ("Odyssey"), a Euronext Amsterdam-listed special-purpose acquisition company, and BenevolentAI, a leading clinical-stage AI drug discovery company, today announced that they have entered into a definitive agreement for a ...

2021-12-06 14:00 2991

Brii Biosciences Included in Hong Kong Stock Connect

DURHAM, N.C. and BEIJING, Dec. 6, 2021 /PRNewswire/ -- Brii Biosciences Limited ("Brii Bio" or the "Company", stock code: 2137.HK), today announced that the Company has been added to the Hong Kong Stock Connect. This inclusion allows eligible domestic investors...

2021-12-06 10:54 4795

Jacobio Receives IND Approval for Combination Therapy of KRAS G12C and Cetuximab Injection in China

BEIJING and SHANGHAI and BOSTON, Dec. 5, 2021 /PRNewswire/ -- Jacobio Pharma ( 1167.HK) has received the Investigational New Drug (the "IND") approval of the combination therapy of KRAS G12C inhibitor JAB-21822 and Cetuximab injection from the Center for Drug Evaluation ofChina (the "CDE") on Dec...

2021-12-06 09:16 3133

Kazia Announces Positive Final Data From Phase II Clinical Study Of Paxalisib In Newly Diagnosed Glioblastoma

SYDNEY, Dec. 4, 2021 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce positive final data from a phase II clinical study of paxalisib as first line therapy in patients with glioblastoma (NCT03522298). The res...

2021-12-04 21:00 5467

Henlius' 4th Biologics: Bevacizumab Biosimilar Hanbeitai Approved by National Medical Products Administration

SHANGHAI, Dec. 4, 2021 /PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696.HK) announced that bevacizumab biosimilar Hanbeitai, developed and manufactured by Henlius independently, has been approved by the National Medical Products Administration (NMPA). It is indicated for the treatment of meta...

2021-12-04 01:51 7012

I-Mab Announces First Two Patients Dosed in U.S. Phase 2 Combination Trial of Uliledlimab with Atezolizumab in Patients with Selected Advanced Solid Tumors

SHANGHAI and GAITHERSBURG, Md., Dec. 3, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced that the first two patients have been dosed in the U.S. p...

2021-12-03 21:00 4151

Biotheus' Bifunctional Therapeutic PM8001 has been Approved by the USFDA to Enter Phase II Studies

ZHUHAI, China, Dec. 3, 2021 /PRNewswire/ -- Biotheus Inc., has announced that its proprietary anti-PD-L1/TGF-β bifunctional therapeutic, named PM8001, has been approved by the USFDA (United States Food and Drug Administration) for conducting clinical phase II studies as part of an international m...

2021-12-03 16:23 2451

Mongolian Government To Build On COVID-19 Vaccine And Booster Success

* Mongolia secures nearly 70% vaccination rates and an overall casualty rate of only 0.3% * Successes against COVID-19 position country well for ambitious and progressive reforms as part of government's Vision 2050 agenda ULAANBAATAR, Mongolia, Dec. 3, 2021 /PRNewswire/ -- Mongolia is prepari...

2021-12-03 15:00 3073

RemeGen's Telitacicept and Disitamab Vedotin Enter China's National Reimbursement Drug List for SLE and Gastric Cancer Treatment

YANTAI, China, Dec. 3, 2021 /PRNewswire/ -- RemeGen Co., Ltd. (9995.HK), a commercial-ready biotechnology company, today announced that two of its innovative drugs, a dual-targeted TACI-Fc fusion protein, Telitacicept (RC18) for treating systemic lupus erythematosus (SLE) and a novel antibody-dru...

2021-12-03 13:45 6180

Innovent and Lilly Announce Successful Expansion of Sintilimab in China National Reimbursement Drug List to Include Three Additional First-Line Indications

SAN FRANCISCO, INDIANAPOLIS, and SUZHOU, China, Dec. 3, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, metabolic, autoimmune and ...

2021-12-03 12:37 5246

Ascletis Announces Inclusion in New Catalogue of China National Reimbursement Drug List (NRDL) of ASCLEVIR®/ GANOVO® Regimen, an All-oral Direct Anti-HCV Therapy

HANGZHOU, China and SHAOXING, China, Dec. 3, 2021 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672) today announces that its all-oral direct anti-hepatitis C virus (HCV) ASCLEVIR® (Ravidasvir)/ GANOVO® (Danoprevir) regimen has been included in the Medicine Catalog for National Basic Medical Insu...

2021-12-03 12:05 5840

InnoCare Announces Inclusion of Orelabrutinib in China National Reimbursement Drug List

BEIJING, Dec. 2, 2021 /PRNewswire/ -- InnoCare Pharma (HKEX: 09969), a commercial-stage biotech company, announced today that its BTK inhibitor orelabrutinib has been included in the updated National Reimbursement Drug List (NRDL) by the China National Healthcare Security Administration (NHSA). ...

2021-12-03 10:13 2761

Decode Genetics Publishes the Largest Ever Study of the Plasma Proteome

REYKJAVIK, Iceland, Dec. 3, 2021 /PRNewswire/ -- In a study published today in Nature genetics, scientists at deCODE genetics , a subsidiary of the pharmaceutical company Amgen, demonstrate how measuring the levels of a large number of proteins in plasma at population scale when combined with dat...

2021-12-03 03:26 4011

Hepagene Therapeutics Initiates the RISE Study, a Phase IIa Clinical Trial of HPG1860 in Patients with NASH

SHANGHAI, Dec. 2, 2021 /PRNewswire/ -- Hepagene Therapeutics, Inc, a clinical stage biopharmaceutical company focusing on innovative therapies for patients with liver diseases, today announced that it has screened the first patient in theUSA for the RISE study, a Phase IIa clinical trial of HPG18...

2021-12-02 23:00 2081

MingMed Biotechnology Announces U.S. FDA Approval for IND Application of HPK1 Small Molecule Inhibitor PRJ1-3024, and Completion of Phase I Clinical Trials for Dry AMD Treatment Drug QA102

GUANGZHOU, China, Dec. 2, 2021 /PRNewswire/ -- MingMed Biotechnology, a clinical stage company dedicated to developing first-in-class pharmaceutical products, announced recently the US Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application for PRJ1-3024, a ...

2021-12-02 22:00 2175

Clarity and Cardinal Health enter into Agreement for Targeted Copper Theranostics

SYDNEY, Dec. 2, 2021 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity"), a clinical-stage radiopharmaceutical company developing next-generation products to address the growing needs in oncology, and Cardinal Health (NYSE: CAH), are pleased to announce that the companies have entered ...

2021-12-02 21:58 2733

Joint CUHK-HKU study discovers efficacy of COVID-19 vaccines correlates with a probiotic bacterium, Bifidobacterium adolescentis

HONG KONG, Dec. 2, 2021 /PRNewswire/ -- The Centre for Gut Microbiota Research of the Faculty of Medicine at TheChinese University of Hong Kong (CU Medicine) is among the first in the world to discover that germs in our gut (gut microbiota) modulate our immunity and disease severity in COVID-19. ...

2021-12-02 21:00 16594

Joint CUHK-HKU study discovers efficacy of COVID-19 vaccines correlates with a probiotic bacterium, Bifidobacterium adolescentis

Publication in The New England Journal of Medicine Confirms that Tens of Thousands of Women with Node-positive, Early-stage Breast Cancer Can Avoid Chemotherapy with the Oncotype DX® Test

- RxPONDER, an independent study led by SWOG Cancer Research Network, demonstrates that guiding treatment with Oncotype DX test can spare chemotherapy use in majority of postmenopausal women - Results have already led to updated NCCN Guidelines® for breast cancer - New RxPONDER results to be fea...

2021-12-02 16:00 3441

Publication in The New England Journal of Medicine Confirms that Tens of Thousands of Women with Node-positive, Early-stage Breast Cancer Can Avoid Chemotherapy with the Oncotype DX® Test

TOT BIOPHARM Announces NMPA Granted Marketing Approval for Pusintin® (TAB008, Bevacizumab Injection) in China

SUZHOU, China, Dec. 2, 2021 /PRNewswire/ -- TOT BIOPHARM International Company Limited (TOT BIOPHARM, 1875.HK) announced its self-developed Pusintin® (TAB008, bevacizumab injection) has been officially granted approval by the National Medical Products Administration ("NMPA") for marketing in main...

2021-12-02 08:00 3937

1 ... 311 312 313314315 316 317 ... 343